Recent Finacing
Recent Raise
Synchroneuron, a Boston-area biopharmaceutical company, is developing SNC-102—a modified acamprosate formulation that modulates glutamate/GABA—and is conducting Phase 2 randomized trials for tardive dyskinesia.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor